Oral Solid Dosage Pharmaceutical Formulation Market Status and Trend Analysis 2017-2026 (COVID-19 Version)
Report Code: KNJ594106 No. of Pages: 150 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
Summary
Further key aspects of the report indicate that:
Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology
Chapter 2: Global Industry Summary
Chapter 3: Market Dynamics
Chapter 4: Global Market Segmentation by region, type and End-Use
Chapter 5: North America Market Segmentation by region, type and End-Use
Chapter 6: Europe Market Segmentation by region, type and End-Use
Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use
Chapter 8: South America Market Segmentation by region, type and End-Use
Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.
Chapter 10: Market Competition by Companies
Chapter 11: Market forecast and environment forecast.
Chapter 12: Industry Summary.
The global Oral Solid Dosage Pharmaceutical Formulation market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.
Based on the type of product, the global Oral Solid Dosage Pharmaceutical Formulation market segmented into
By Form
Capsules
Powders
Tablets
By Drug Release Mechanism
Immediate Release
Extended Release
Based on the end-use, the global Oral Solid Dosage Pharmaceutical Formulation market classified into
Hospitals
Clinics
Other
Based on geography, the global Oral Solid Dosage Pharmaceutical Formulation market segmented into
North America [U.S., Canada, Mexico]
Europe [Germany, UK, France, Italy, Rest of Europe]
Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]
South America [Brazil, Argentina, Rest of Latin America]
Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]
And the major players included in the report are
AstraZeneca Plc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Gilead Sciences
Merck & Co. Inc.
Novartis AG
Pfizer Inc.
AbbVie Inc.
Boehringer Ingelheim GmbH
Hoffman-La-Roche Ltd.
Johnson & Johnson
Biogen Inc.
Bayer AG
Teva Pharmaceticals
Amgen Inc.
Takeda Pharmaceutical Company Ltd.
Otsuka Pharmaceutical Co., Ltd.
Shire Plc.
Celgene Corporation
Astellas Pharma Inc. Table of Contents
1 RESEARCH SCOPE
1.1 Research Product Definition
1.2 Research Segmentation
1.2.1 Product Type
1.2.2 Main product Type of Major Players
1.3 Demand Overview
1.4 Research Methodology
2 GLOBAL ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION INDUSTRY
2.1 Summary about Oral Solid Dosage Pharmaceutical Formulation Industry
2.2 Oral Solid Dosage Pharmaceutical Formulation Market Trends
2.2.1 Oral Solid Dosage Pharmaceutical Formulation Production & Consumption Trends
2.2.2 Oral Solid Dosage Pharmaceutical Formulation Demand Structure Trends
2.3 Oral Solid Dosage Pharmaceutical Formulation Cost & Price
3 MARKET DYNAMICS
3.1 Manufacturing & Purchasing Behavior in 2020
3.2 Market Development under the Impact of COVID-19
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunity
3.2.4 Risk
4 GLOBAL MARKET SEGMENTATION
4.1 Region Segmentation (2017 to 2021f)
4.1.1 North America (U.S., Canada and Mexico)
4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
4.2 Product Type Segmentation (2017 to 2021f)
4.2.1 By Form
4.2.2 Capsules
4.2.3 Powders
4.2.4 Tablets
4.2.5 By Drug Release Mechanism
4.2.6 Immediate Release
4.2.7 Extended Release
4.3 Consumption Segmentation (2017 to 2021f)
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Other
5 NORTH AMERICA MARKET SEGMENT
5.1 Region Segmentation (2017 to 2021f)
5.1.1 U.S.
5.1.2 Canada
5.1.3 Mexico
5.2 Product Type Segmentation (2017 to 2021f)
5.2.1 By Form
5.2.2 Capsules
5.2.3 Powders
5.2.4 Tablets
5.2.5 By Drug Release Mechanism
5.2.6 Immediate Release
5.2.7 Extended Release
5.3 Consumption Segmentation (2017 to 2021f)
5.3.1 Hospitals
5.3.2 Clinics
5.3.3 Other
5.4 Impact of COVID-19 in North America
6 EUROPE MARKET SEGMENTATION
6.1 Region Segmentation (2017 to 2021f)
6.1.1 Germany
6.1.2 UK
6.1.3 France
6.1.4 Italy
6.1.5 Rest of Europe
6.2 Product Type Segmentation (2017 to 2021f)
6.2.1 By Form
6.2.2 Capsules
6.2.3 Powders
6.2.4 Tablets
6.2.5 By Drug Release Mechanism
6.2.6 Immediate Release
6.2.7 Extended Release
6.3 Consumption Segmentation (2017 to 2021f)
6.3.1 Hospitals
6.3.2 Clinics
6.3.3 Other
6.4 Impact of COVID-19 in Europe
7 ASIA-PACIFIC MARKET SEGMENTATION
7.1 Region Segmentation (2017 to 2021f)
7.1.1 China
7.1.2 India
7.1.3 Japan
7.1.4 South Korea
7.1.5 Southeast Asia
7.1.6 Australia
7.1.7 Rest of Asia Pacific
7.2 Product Type Segmentation (2017 to 2021f)
7.2.1 By Form
7.2.2 Capsules
7.2.3 Powders
7.2.4 Tablets
7.2.5 By Drug Release Mechanism
7.2.6 Immediate Release
7.2.7 Extended Release
7.3 Consumption Segmentation (2017 to 2021f)
7.3.1 Hospitals
7.3.2 Clinics
7.3.3 Other
7.4 Impact of COVID-19 in Europe
8 SOUTH AMERICA MARKET SEGMENTATION
8.1 Region Segmentation (2017 to 2021f)
8.1.1 Brazil
8.1.2 Argentina
8.1.3 Rest of Latin America
8.2 Product Type Segmentation (2017 to 2021f)
8.2.1 By Form
8.2.2 Capsules
8.2.3 Powders
8.2.4 Tablets
8.2.5 By Drug Release Mechanism
8.2.6 Immediate Release
8.2.7 Extended Release
8.3 Consumption Segmentation (2017 to 2021f)
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Other
8.4 Impact of COVID-19 in Europe
9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION
9.1 Region Segmentation (2017 to 2021f)
9.1.1 GCC
9.1.2 North Africa
9.1.3 South Africa
9.1.4 Rest of Middle East and Africa
9.2 Product Type Segmentation (2017 to 2021f)
9.2.1 By Form
9.2.2 Capsules
9.2.3 Powders
9.2.4 Tablets
9.2.5 By Drug Release Mechanism
9.2.6 Immediate Release
9.2.7 Extended Release
9.3 Consumption Segmentation (2017 to 2021f)
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Other
9.4 Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
10.1 Brief Introduction of Major Players
10.1.1 AstraZeneca Plc.
10.1.2 Bristol-Myers Squibb Company
10.1.3 Eli Lilly and Company
10.1.4 Gilead Sciences
10.1.5 Merck & Co. Inc.
10.1.6 Novartis AG
10.1.7 Pfizer Inc.
10.1.8 AbbVie Inc.
10.1.9 Boehringer Ingelheim GmbH
10.1.10 Hoffman-La-Roche Ltd.
10.1.11 Johnson & Johnson
10.1.12 Biogen Inc.
10.1.13 Bayer AG
10.1.14 Teva Pharmaceticals
10.1.15 Amgen Inc.
10.1.16 Takeda Pharmaceutical Company Ltd.
10.1.17 Otsuka Pharmaceutical Co., Ltd.
10.1.18 Shire Plc.
10.1.19 Celgene Corporation
10.1.20 Astellas Pharma Inc.
10.2 Oral Solid Dosage Pharmaceutical Formulation Sales Date of Major Players (2017-2020e)
10.2.1 AstraZeneca Plc.
10.2.2 Bristol-Myers Squibb Company
10.2.3 Eli Lilly and Company
10.2.4 Gilead Sciences
10.2.5 Merck & Co. Inc.
10.2.6 Novartis AG
10.2.7 Pfizer Inc.
10.2.8 AbbVie Inc.
10.2.9 Boehringer Ingelheim GmbH
10.2.10 Hoffman-La-Roche Ltd.
10.2.11 Johnson & Johnson
10.2.12 Biogen Inc.
10.2.13 Bayer AG
10.2.14 Teva Pharmaceticals
10.2.15 Amgen Inc.
10.2.16 Takeda Pharmaceutical Company Ltd.
10.2.17 Otsuka Pharmaceutical Co., Ltd.
10.2.18 Shire Plc.
10.2.19 Celgene Corporation
10.2.20 Astellas Pharma Inc.
10.3 Market Distribution of Major Players
10.4 Global Competition Segmentation
11 MARKET FORECAST
11.1 Forecast by Region
11.2 Forecast by Demand
11.3 Environment Forecast
11.3.1 Impact of COVID-19
11.3.2 Geopolitics Overview
11.3.3 Economic Overview of Major Countries
12 REPORT SUMMARY STATEMENT NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com